Section Arrow
Quote
OTLK.NASDAQ
- Outlook Therapeutics
(Financial Status)
Quotes are at least 15-min delayed:2026/06/02 05:13 EDT
Pre Market
Last
 0.9128
+0.0698 (+8.28%)
Bid
0.9128
Ask
0.92
High 0.9726 
Low 0.8924 
Volume 716.97K 
Regular Hours (Closed)
Last
 0.843
+0.113 (+15.48%)
Day High 
0.9428 
Prev. Close
0.73 
1-M High
0.82 
Volume 
44.17M 
Bid
0.9128
Ask
0.92
Day Low
0.72 
Open
0.7449 
1-M Low
0.2066 
Market Cap 
88.23M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 0.41 
20-SMA 0.32 
50-SMA 0.28 
52-W High 3.39 
52-W Low 0.1611 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.13/-0.27
Enterprise Value
88.42M
Balance Sheet
Book Value Per Share
-0.20
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
1.41M
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
AIMAIM ImmunoTech Inc.0.8986+0.4908+120.35%-- 
Pre Market 0.833 -0.0656 -7.30%
GNTAGenenta Science SpA1.65+0.62+60.19%-- 
Pre Market 1.6503 +0.0003 +0.02%
OTLKOutlook Therapeutics0.843+0.113+15.48%-- 
Pre Market 0.9128 +0.0698 +8.28%
ADTXAditxt Inc.0.113-0.0042-3.58%-- 
Pre Market 0.0988 -0.0142 -12.57%
RXRXRecursion Pharmaceuticals3.79+0.2+5.57%-- 
Pre Market 3.73 -0.06 -1.58%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorizationfor an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.